Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 57,400 shares, a decrease of 30.1% from the May 15th total of 82,100 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 64,800 shares, the short-interest ratio is presently 0.9 days.
Alzamend Neuro Stock Down 19.8 %
Shares of Alzamend Neuro stock opened at $0.45 on Friday. The company’s fifty day simple moving average is $0.65 and its two-hundred day simple moving average is $0.85. Alzamend Neuro has a 12-month low of $0.44 and a 12-month high of $10.65. The firm has a market cap of $3.35 million, a PE ratio of -0.46 and a beta of 0.09.
Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last posted its earnings results on Monday, March 25th. The company reported ($0.38) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Alzamend Neuro
About Alzamend Neuro
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Featured Stories
- Five stocks we like better than Alzamend Neuro
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 6/10 – 6/14
- What is a SEC Filing?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- What Are Trending Stocks? Trending Stocks Explained
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.